A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
Eli Lilly and Company
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- ATTAIN-CN
- status
- NOT_YET_RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 192
- sponsor
- Eli Lilly and Company
- conditions
- Obesity; Overweight
- interventions
- DRUG: Orforglipron; DRUG: Placebo
- start date
- 2026-12-01
- start date type
- ESTIMATED
- primary completion date
- 2028-03-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07790861
- Published
- Aug 27, 2026
- Updated
- Oct 13, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07790861
- Categories
- Obesity, Overweight
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials